Published in N Engl J Med on August 10, 2006
Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer | NCT00003006
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 3.96
Retracted science and the retraction index. Infect Immun (2011) 3.35
Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst (2010) 3.30
Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A (2009) 2.84
Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation (2009) 2.70
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
New molecularly targeted therapies for lung cancer. J Clin Invest (2007) 1.86
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One (2007) 1.86
Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax (2010) 1.80
Comparative study of gene set enrichment methods. BMC Bioinformatics (2009) 1.74
Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol (2013) 1.74
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res (2008) 1.63
Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol (2009) 1.52
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics (2010) 1.50
Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res (2008) 1.49
A policy approach to the development of molecular diagnostic tests. Nat Biotechnol (2010) 1.46
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol (2012) 1.46
Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn (2007) 1.44
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest (2007) 1.41
Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol (2010) 1.37
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol (2010) 1.29
A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res (2010) 1.21
Integrating the MicroRNome into the study of lung disease. Am J Respir Crit Care Med (2008) 1.19
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res (2009) 1.19
Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med (2010) 1.19
Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One (2010) 1.17
Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A (2008) 1.14
Gamma-Normal-Gamma mixture model for detecting differentially methylated loci in three breast cancer cell lines. Cancer Inform (2007) 1.12
Update in lung cancer 2008. Am J Respir Crit Care Med (2009) 1.11
Discovery of the gene signature for acute lung injury in patients with sepsis. Physiol Genomics (2009) 1.10
Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. Br J Cancer (2011) 1.09
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol (2009) 1.09
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
Gene expression profiling of non-small cell lung cancer. Lung Cancer (2008) 1.08
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer (2008) 1.07
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics (2008) 1.05
Impact and interactions between smoking and traditional prognostic factors in lung cancer progression. Lung Cancer (2009) 1.03
Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med (2008) 1.03
An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics (2008) 1.02
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res (2011) 1.00
Update in lung cancer 2007. Am J Respir Crit Care Med (2008) 1.00
Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet (2011) 0.99
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res (2009) 0.98
Predicting the future for people with lung cancer. Nat Med (2008) 0.97
Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol (2009) 0.97
A novel network model identified a 13-gene lung cancer prognostic signature. Int J Comput Biol Drug Des (2011) 0.96
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem (2009) 0.95
Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo. Genome Biol (2008) 0.95
Genomics of lung cancer. Proc Am Thorac Soc (2009) 0.94
The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis (2010) 0.93
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther (2010) 0.93
Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med (2007) 0.91
Data mining in genomics. Clin Lab Med (2008) 0.90
Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol (2009) 0.90
CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer. Cancer (2010) 0.89
Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer (2009) 0.88
Immune signatures predict prognosis in localized cancer. Cancer Invest (2010) 0.88
The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. Am J Pathol (2009) 0.88
Genetic variations in epigenetic genes are predictors of recurrence in stage I or II non-small cell lung cancer patients. Clin Cancer Res (2012) 0.88
Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist (2010) 0.88
CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumour Biol (2014) 0.87
Study designs and statistical analyses for biomarker research. Sensors (Basel) (2012) 0.86
Lung cancer progression and metastasis from the prognostic point of view. Clin Exp Metastasis (2010) 0.86
A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg (2008) 0.86
Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase. J Biol Chem (2011) 0.85
Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One (2011) 0.84
Clinical impact of high-throughput gene expression studies in lung cancer. J Thorac Oncol (2009) 0.84
HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner. Oncol Lett (2010) 0.84
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol (2010) 0.84
A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget (2015) 0.84
Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients. Clin Lung Cancer (2011) 0.84
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J (2009) 0.84
Lung cancer: developmental networks gone awry? Cancer Biol Ther (2009) 0.83
Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clin Cancer Res (2011) 0.82
A 10-gene progenitor cell signature predicts poor prognosis in lung adenocarcinoma. Ann Thorac Surg (2011) 0.82
A Novel Network Model for Molecular Prognosis. ACM Int Conf Bioinform Comput Biol (2010) (2015) 0.82
Molecular prognostic prediction for locally advanced nasopharyngeal carcinoma by support vector machine integrated approach. PLoS One (2012) 0.81
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. Ther Clin Risk Manag (2007) 0.81
Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray study. BMC Cancer (2010) 0.81
Genomics for disease treatment and prevention. Psychiatr Clin North Am (2010) 0.81
Expression levels of some antioxidant and epidermal growth factor receptor genes in patients with early-stage non-small cell lung cancer. J Nucleic Acids (2010) 0.80
Innate immunity and hepatitis C virus infection: a microarray's view. Infect Agent Cancer (2012) 0.80
Adjuvant therapy for resected non-small cell lung cancer. Ther Adv Med Oncol (2009) 0.80
Update in lung cancer 2006. Am J Respir Crit Care Med (2007) 0.79
Module-based prediction approach for robust inter-study predictions in microarray data. Bioinformatics (2010) 0.79
Support vector machine-based nomogram predicts postoperative distant metastasis for patients with oesophageal squamous cell carcinoma. Br J Cancer (2013) 0.79
Predicting recurrence using the clinical factors of patients with non-small cell lung cancer after curative resection. J Korean Med Sci (2009) 0.78
Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res (2014) 0.78
Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. PLoS One (2010) 0.78
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg (2010) 4.23
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (2009) 4.17
Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg (2007) 4.15
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Thoracoscopic lobectomy is a safe and versatile procedure: experience with 500 consecutive patients. Ann Surg (2006) 3.32
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
Statistical mixture modeling for cell subtype identification in flow cytometry. Cytometry A (2008) 3.06
Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. J Thorac Cardiovasc Surg (2009) 3.06
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg (2003) 2.73
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation (2009) 2.70
High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest (2009) 2.66
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation (2006) 2.51
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg (2004) 2.41
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Understanding GPU Programming for Statistical Computation: Studies in Massively Parallel Massive Mixtures. J Comput Graph Stat (2010) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet (2010) 2.34
Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons Database analysis. Ann Surg (2012) 2.33
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol (2009) 2.21
Risk factors for morbidity after lobectomy for lung cancer in elderly patients. Ann Thorac Surg (2009) 2.19
Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg (2007) 2.17
General conditions for predictivity in learning theory. Nature (2004) 2.16
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
The Biomedical Resource Ontology (BRO) to enable resource discovery in clinical and translational research. J Biomed Inform (2010) 2.10
Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet (2011) 2.10
A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg (2003) 2.07
Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet (2011) 2.06